Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2451 to 2460 of 2733 total matches.

A Percutaneous Device (MitraClip) for Mitral Regurgitation

   
The Medical Letter on Drugs and Therapeutics • Dec 23, 2013  (Issue 1432)
surgery for mitral valve dysfunction.1 At 4 years, the primary composite endpoint persisted in 40 ...
The FDA has approved the use of a transcatheter mitral valve device (MitraClip – Abbott) for percutaneous treatment of significant symptomatic degenerative mitral regurgitation (grade 3-4+) in patients who are at prohibitive risk for mitral valve surgery. It is the first percutaneous nonsurgical treatment approved for this indication.
Med Lett Drugs Ther. 2013 Dec 23;55(1432):103-4 |  Show IntroductionHide Introduction

Durlaza - A 24-Hour Extended-Release Aspirin

   
The Medical Letter on Drugs and Therapeutics • Jan 18, 2016  (Issue 1486)
at the end of the 24-hour dosing interval.1 An ER formulation that releases acetylsalicylic acid (ASA) over ...
The FDA has approved Durlaza (New Haven Pharmaceuticals), a 24-hour extended-release (ER) aspirin formulation available only by prescription, for secondary prevention of myocardial infarction (MI) and stroke.
Med Lett Drugs Ther. 2016 Jan 18;58(1486):7 |  Show IntroductionHide Introduction

Table: Over the Counter At-Home Tests for COVID-19 (online only)

   
The Medical Letter on Drugs and Therapeutics • Oct 20, 2021  (Issue 5041)
Overall: 92%/98% No Yes6 75.00 Test Kit (Lucira) minutes Symptomatic: 94%/98% (1 ct)7 Asymptomatic: 90 ...
View the Table: Over the Counter At-Home Tests for COVID-19
Med Lett Drugs Ther. 2021 Oct 20;63(5041):e1   doi:10.58347/tml.2021.5041a |  Show IntroductionHide Introduction

Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Constipation (IBS-C) (online only)

   
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025  (Issue 1721)
) 5.8 g/teaspoon powder; 5.8 g packets; 1.8 g caps; 2 g wafers $29.00 10-35 g/day in 2-3 divided ...
View the Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Constipation (IBS-C)
Med Lett Drugs Ther. 2025 Feb 3;67(1721):e1-3   doi:10.58347/tml.2025.1721e |  Show IntroductionHide Introduction

Lunsotogene Parvec (Otarmeni) for Hearing Loss (online only)

   
The Medical Letter on Drugs and Therapeutics • Oct 12, 2026  (Issue 1765)
otoferlin.1 CLINICAL STUDIES — Accelerated approval of lunsotogene parvec was based on the results ...
Lunsotogene parvec (Otarmeni – Regeneron), an adeno-associated viral vector-based gene therapy, has received accelerated approval from the FDA for treatment of severe-to-profound or profound sensorineural hearing loss (any frequency >90 decibels hearing level [dB HL]) in patients with confirmed variants in both copies of the otoferlin (OTOF) gene. It is the first gene therapy to be approved in the US for genetic hearing loss.
Med Lett Drugs Ther. 2026 Oct 12;68(1765):e169   doi:10.58347/tml.2026.1765d |  Show IntroductionHide Introduction

Comparison Chart: Antiviral Drugs for Seasonal Influenza (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 09, 2026  (Issue 1767)
-approved for chemoprophylaxis of influenza in patients ≥1 year old $48.00 152.00 Peramivir – Rapivab ...
View the Comparison Chart: Antiviral Drugs for Seasonal Influenza
Med Lett Drugs Ther. 2026 Nov 9;68(1767):e180-3   doi:10.58347/tml.2026.1767c |  Show IntroductionHide Introduction

In Brief: Statins for Primary Prevention in Older Adults

   
The Medical Letter on Drugs and Therapeutics • Nov 23, 2026  (Issue 1768)
) are the drugs of choice for lowering low-density lipoprotein cholesterol (LDL-C).1 They reduce the risk ...
HMG-CoA reductase inhibitors (statins) are the drugs of choice for lowering low-density lipoprotein cholesterol (LDL-C). They reduce the risk of primary and secondary atherosclerotic cardiovascular disease (ASCVD) events and death, but data supporting their efficacy and safety in older adults have been lacking. Guidelines recommend weighing the potential risks and benefits when deciding whether to start or stop statin therapy for primary prevention in adults >75 years old. Results of a trial evaluating statin initiation for primary prevention of ASCVD in older persons have recently...
Med Lett Drugs Ther. 2026 Nov 23;68(1768):191   doi:10.58347/tml.2026.1768e |  Show IntroductionHide Introduction

Corrections: Drugs for Diabetes & Another Insulin Glargine (Basaglar) for Diabetes

   
The Medical Letter on Drugs and Therapeutics • Jan 30, 2017  (Issue 1513)
Corrections Drugs for Diabetes (Med Lett Drugs Ther 2017; 59:9) In the 4th paragraph of the GLP-1 ...
Drugs for Diabetes (Med Lett Drugs Ther 2017; 59:9)In the 4th paragraph of the GLP-1 receptor agonists section, we mistakenly stated that Xultophy 100/3.6 is a combination of insulin degludec and albiglutide; Xultophy 100/3.6 is a combination of insulin degludec and liraglutide.Another Insulin Glargine (Basaglar) for Diabetes (Med Lett Drugs Ther 2017; 59:3)In the Dosage and Administration section, we removed the word "syringe" to describe Basaglar's KwikPen device. Basaglar is not available as a prefilled syringe; it is only available as a KwikPen.Download complete U.S. English...
Med Lett Drugs Ther. 2017 Jan 30;59(1513):26 |  Show IntroductionHide Introduction

Smallpox Vaccine

   
The Medical Letter on Drugs and Therapeutics • Jan 06, 2003  (Issue 1147)
) FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS 1 Vaccination — Smallpox ...
Because of concerns about the possibility of bioterrorism involving smallpox, the US government is reinstituting smallpox vaccination (https://www.cdc.gov/smallpox/; www.idsociety.org/bt/toc.htm). Vaccination is currently expected to proceed in three phases: the military and hospital smallpox response teams first, other health care workers, police and firefighters second, and the general public in the third phase. Except for the military, vaccination will be...
Med Lett Drugs Ther. 2003 Jan 6;45(1147):1-3 |  Show IntroductionHide Introduction

Alendronate and Risedronate

   
The Medical Letter on Drugs and Therapeutics • Apr 25, 2005  (Issue 1207)
% of the alendronatetreated women. 1 After 5 years, placebo-treated patients were discharged from the study. Patients ...
A 10-year study of daily oral alendronate (Fosamax) and a 7-year study of daily oral risedronate (Actonel) indicate that both drugs maintained increases in bone mineral density (BMD) and decreases in markers of bone remodeling throughout the study period. Both drugs are now more commonly taken once weekly. Available data are insufficient to compare fracture rates with alendronate and risedronate, and fracture rates are considered the most important endpoint in osteoporosis studies. Recent reports of severe pain and jaw osteonecrosis with these drugs are disturbing.
Med Lett Drugs Ther. 2005 Apr 25;47(1207):33-5 |  Show IntroductionHide Introduction